The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

New study shows dementia patients who are on antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

The American Heart Association issued a scientific statement highlighting the significance of mental health in maternal CV ...

Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.

This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...

A recently retired U.S. senator is calling on the Arizona legislature to pass a bill to fund clinical trials into ibogaine, ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.